HIV-1 Tat-specific IgG antibodies in high-responders target a B-cell epitope in the cysteine-rich domain and block extracellular Tat efficiently

Vaccine

Volumn 27, Issue 48, 2009, Pages 6739-6747

  Kashi, Venkatesh Prasanna ^a   Jacob, Rajesh Abraham ^a   Paul, Siddhartha ^a   Nayak, Kaustuv ^b   Satish, Bhuthiah ^c   Swaminathan, Soumya ^b   Satish, Kadappa S ^c   Ranga, Udaykumar ^a  

^a JAWAHARLAL NEHRU CENTRE FOR ADVANCED SCIENTIFIC RESEARCH   (India)

^b NATIONAL INSTITUTE FOR RESEARCH IN TUBERCULOSIS   (India)

^c Seva Clinic   (India)

Author keywords

Affinity maturation; HIV 1; Humoral immune response; IgG; India; Isotype switch; Natural antibody; Subtype C; Tat; Tat vaccine

Indexed keywords

ANTIBODY; CYSTEINE; EPITOPE; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1; TAT ANTIBODY; TAT VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; B LYMPHOCYTE; CLADISTICS; CONTROLLED STUDY; CROSS REACTION; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; IMMUNE RESPONSE; INDIA; INDIAN; KNOWLEDGE; MAJOR CLINICAL STUDY; MALE; POPULATION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN INTERACTION; SAMPLE;

ADOLESCENT; ADULT; ANTIBODY AFFINITY; CROSS REACTIONS; CROSS-SECTIONAL STUDIES; EPITOPE MAPPING; EPITOPES, B-LYMPHOCYTE; FEMALE; HIV ANTIBODIES; HIV INFECTIONS; HIV SEROPOSITIVITY; HIV-1; HUMANS; IMMUNITY, HUMORAL; IMMUNODOMINANT EPITOPES; IMMUNOGLOBULIN CLASS SWITCHING; IMMUNOGLOBULIN G; INDIA; MALE; MIDDLE AGED; NEUTRALIZATION TESTS; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; YOUNG ADULT;

EID: 70350769107     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.08.078     Document Type: Article

References (50)

1. Jeang K.T., Xiao H., and Rich E.A. Multifaceted activities of the HIV-1 transactivator of transcription. Tat J Biol Chem 274 41 (1999) 28837-28840
2. Huigen M.C., Kamp W., and Nottet H.S. Multiple effects of HIV-1 trans-activator protein on the pathogenesis of HIV-1 infection. Eur J Clin Invest 34 1 (2004) 57-66
3. Gupta S., Boppana R., Mishra G.C., Saha B., and Mitra D. HIV-1 Tat suppresses gp120-specific T cell response in IL-10-dependent manner. J Immunol 180 1 (2008) 79-88
4. Wieland U., Kuhn J.E., Jassoy C., Rubsamen-Waigmann H., Wolber V., and Braun R.W. Antibodies to recombinant HIV-1 vif, tat, and nef proteins in human sera. Med Microbiol Immunol (Berl) 179 1 (1990) 1-11
5. Viscidi R.P., Mayur K., Lederman H.M., and Frankel A.D. Inhibition of antigen-induced lymphocyte proliferation by Tat protein from HIV-1. Science 246 4937 (1989) 1606-1608
6. Badou A., Bennasser Y., Moreau M., Leclerc C., Benkirane M., and Bahraoui E. Tat protein of human immunodeficiency virus type 1 induces interleukin-10 in human peripheral blood monocytes: implication of protein kinase C-dependent pathway. J Virol 74 22 (2000) 10551-10562
7. Zocchi M.R., Contini P., Alfano M., and Poggi A. Pertussis toxin (PTX) B subunit and the nontoxic PTX mutant PT9K/129G inhibit Tat-induced TGF-beta production by NK cells and TGF-beta-mediated NK cell apoptosis. J Immunol 174 10 (2005) 6054-6061
8. Reinhold D., Wrenger S., Kahne T., and Ansorge S. HIV-1 Tat: immunosuppression via TGF-beta1 induction. Immunol Today 20 8 (1999) 384-385
9. Zagury D., Lachgar A., Chams V., Fall L.S., Bernard J., Zagury J.F., et al. Interferon alpha and Tat involvement in the immunosuppression of uninfected T cells and C-C chemokine decline in AIDS. Proc Natl Acad Sci USA 95 7 (1998) 3851-3856
10. Gonzalez E., Punzon C., Gonzalez M., and Fresno M. HIV-1 Tat inhibits IL-2 gene transcription through qualitative and quantitative alterations of the cooperative Rel/AP1 complex bound to the CD28RE/AP1 composite element of the IL-2 promoter. J Immunol 166 7 (2001) 4560-4569
11. Ito M., Ishida T., He L., Tanabe F., Rongge Y., Miyakawa Y., et al. HIV type 1 Tat protein inhibits interleukin 12 production by human peripheral blood mononuclear cells. AIDS Res Hum Retroviruses 14 10 (1998) 845-849
12. Lefevre E.A., Krzysiek R., Loret E.P., Galanaud P., and Richard Y. HIV-1 tat protein differentially modulates the B cell response of naive, memory, and germinal center B cells. J Immunol 163 3 (1999) 1119-1122
13. Cohen S.S., Li C., Ding L., Cao Y., Pardee A.B., Shevach E.M., et al. Pronounced acute immunosuppression in vivo mediated by HIV Tat challenge. Proc Natl Acad Sci USA 96 19 (1999) 10842-10847
14. Cui Z., Patel J., Tuzova M., Ray P., Phillips R., Woodward J.G., et al. Strong T cell type-1 immune responses to HIV-1 Tat (1-72) protein-coated nanoparticles. Vaccine 22 20 (2004) 2631-2640
15. Gavioli R., Cellini S., Castaldello A., Voltan R., Gallerani E., Gagliardoni F., et al. The Tat protein broadens T cell responses directed to the HIV-1 antigens Gag and Env: implications for the design of new vaccination strategies against AIDS. Vaccine 26 5 (2008) 727-737
16. Fanales-Belasio E., Moretti S., Nappi F., Barillari G., Micheletti F., Cafaro A., et al. Native HIV-1 Tat protein targets monocyte-derived dendritic cells and enhances their maturation, function, and antigen-specific T cell responses. J Immunol 168 1 (2002) 197-206
17. Fanales-Belasio E., Moretti S., Fiorelli V., Tripiciano A., Pavone Cossut M.R., Scoglio A., et al. HIV-1 Tat addresses dendritic cells to induce a predominant Th1-type adaptive immune response that appears prevalent in the asymptomatic stage of infection. J Immunol 182 5 (2009) 2888-2897
18. Gavioli R., Gallerani E., Fortini C., Fabris M., Bottoni A., Canella A., et al. HIV-1 Tat protein modulates the generation of cytotoxic T cell epitopes by modifying proteasome composition and enzymatic activity. J Immunol 173 6 (2004) 3838-3843
19. Krone W.J., Debouck C., Epstein L.G., Heutink P., Meloen R., and Goudsmit J. Natural antibodies to HIV-tat epitopes and expression of HIV-1 genes in vivo. J Med Virol 26 3 (1988) 261-270
20. Reiss P., Lange J.M., De Ronde A., de Wolf F., Dekker J., Debouck C., et al. Speed of progression to AIDS and degree of antibody response to accessory gene products of HIV-1. J Med Virol 30 3 (1990) 163-168
21. Richardson M.W., Mirchandani J., Duong J., Grimaldo S., Kocieda V., Hendel H., et al. Antibodies to Tat and Vpr in the GRIV cohort: differential association with maintenance of long-term non-progression status in HIV-1 infection. Biomed Pharmacother 57 1 (2003) 4-14
22. Re M.C., Vignoli M., Furlini G., Gibellini D., Colangeli V., Vitone F., et al. Antibodies against full-length Tat protein and some low-molecular-weight Tat-peptides correlate with low or undetectable viral load in HIV-1 seropositive patients. J Clin Virol 21 1 (2001) 81-89
23. Senkaali D., Kebba A., Shafer L.A., Campbell G.R., Loret E.P., Van Der P.L., et al. Tat-specific binding IgG and disease progression in HIV type 1-infected Ugandans. AIDS Res Hum Retroviruses 24 4 (2008) 587-594
24. Tahtinen M., Ranki A., Valle S.L., Ovod V., and Krohn K. B-cell epitopes in HIV-1 Tat and Rev proteins colocalize with T-cell epitopes and with functional domains. Biomed Pharmacother 51 10 (1997) 480-487
25. Goulder P.J., Addo M.M., Altfeld M.A., Rosenberg E.S., Tang Y., Govender U., et al. Rapid definition of five novel HLA-A*3002-restricted human immunodeficiency virus-specific cytotoxic T-lymphocyte epitopes by elispot and intracellular cytokine staining assays. J Virol 75 3 (2001) 1339-1347
26. Lieberman J., Fabry J.A., Fong D.M., and Parkerson G.R. Recognition of a small number of diverse epitopes dominates the cytotoxic T lymphocytes response to HIV type 1 in an infected individual. AIDS Res Hum Retroviruses 13 5 (1997) 383-392
27. Re M.C., Furlini G., Vignoli M., Ramazzotti E., Zauli G., and La Placa M. Antibody against human immunodeficiency virus type 1 (HIV-1) Tat protein may have influenced the progression of AIDS in HIV-1-infected hemophiliac patients. Clin Diagn Lab Immunol 3 2 (1996) 230-232
28. Rodman T.C., Pruslin F.H., To S.E., and Winston R. Human immunodeficiency virus (HIV) Tat-reactive antibodies present in normal HIV-negative sera and depleted in HIV-positive sera. Identification of the epitope. J Exp Med 175 5 (1992) 1247-1253
29. van Baalen C.A., Pontesilli O., Huisman R.C., Geretti A.M., Klein M.R., de Wolf F., et al. Human immunodeficiency virus type 1 Rev- and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS. J Gen Virol 78 Pt 8 (1997) 1913-1918
30. Rezza G., Fiorelli V., Dorrucci M., Ciccozzi M., Tripiciano A., Scoglio A., et al. The presence of anti-Tat antibodies is predictive of long-term nonprogression to AIDS or severe immunodeficiency: findings in a cohort of HIV-1 seroconverters. J Infect Dis 191 8 (2005) 1321-1324
31. Zagury J.F., Sill A., Blattner W., Lachgar A., Le Buanec H., Richardson M., et al. Antibodies to the HIV-1 Tat protein correlated with nonprogression to AIDS: a rationale for the use of Tat toxoid as an HIV-1 vaccine. J Hum Virol 1 4 (1998) 282-292
32. Rodman T.C., Lutton J.D., Jiang S., Al Kouatly H.B., and Winston R. Circulating natural IgM antibodies and their corresponding human cord blood cell-derived Mabs specifically combat the Tat protein of HIV. Exp Hematol 29 8 (2001) 1004-1009
33. Stittelaar K.J., Gruters R.A., Schutten M., van Baalen C.A., van Amerongen G., Cranage M., et al. Comparison of the efficacy of early versus late viral proteins in vaccination against SIV. Vaccine 20 23-24 (2002) 2921-2927
34. Re M.C., Gibellini D., Furlini G., Vignoli M., Vitone F., Bon I., et al. Relationships between the presence of anti-Tat antibody. DNA and RNA viral load. New Microbiol 24 3 (2001) 207-215
35. Siddappa N.B., Dash P.K., Mahadevan A., Desai A., Jayasuryan N., Ravi V., et al. Identification of unique B/C recombinant strains of HIV-1 in the southern state of Karnataka, India. AIDS 19 13 (2005) 1426-1429
36. Siddappa N.B., Venkatramanan M., Venkatesh P., Janki M.V., Jayasuryan N., Desai A., et al. Transactivation and signaling functions of Tat are not correlated: biological and immunological characterization of HIV-1 subtype-C Tat protein. Retrovirology 3 1 (2006) 53
37. Ramakrishna L., Anand K.K., Mohankumar K.M., and Ranga U. Codon optimization of the Tat antigen of human immunodeficiency virus type 1 generates strong immune responses in mice following genetic immunization. J Virol 78 17 (2004) 9174-9189
38. Pullen G.R., Fitzgerald M.G., and Hosking C.S. Antibody avidity determination by ELISA using thiocyanate elution. J Immunol Methods 86 1 (1986) 83-87
39. Siddappa N.B., Dash P.K., Mahadevan A., Jayasuryan N., Hu F., Dice B., et al. Identification of subtype C human immunodeficiency virus type 1 by subtype-specific PCR and its use in the characterization of viruses circulating in the southern parts of India. J Clin Microbiol 42 6 (2004) 2742-2751
40. Ranga U., Shankarappa R., Siddappa N.B., Ramakrishna L., Nagendran R., Mahalingam M., et al. Tat protein of human immunodeficiency virus type 1 subtype C strains is a defective chemokine. J Virol 78 5 (2004) 2586-2590
41. Butto S., Fiorelli V., Tripiciano A., Ruiz-Alvarez M.J., Scoglio A., Ensoli F., et al. Sequence conservation and antibody cross-recognition of clade B human immunodeficiency virus (HIV) type 1 Tat protein in HIV-1-infected Italians, Ugandans, and South Africans. J Infect Dis 188 8 (2003) 1171-1180
42. Campbell G.R., Senkaali D., Watkins J., Esquieu D., Opi S., Yirrell D.L., et al. Tat mutations in an African cohort that do not prevent transactivation but change its immunogenic properties. Vaccine 25 50 (2007) 8441-8447
43. Re M.C., Furlini G., Vignoli M., Ramazzotti E., Roderigo G., De Rosa V., et al. Effect of antibody to HIV-1 Tat protein on viral replication in vitro and progression of HIV-1 disease in vivo. J Acquir Immune Defic Syndr Hum Retrovirol 10 4 (1995) 408-416
44. Reiss P., de Wolf F., Kuiken C.L., De Ronde A., Dekker J., Boucher C.A., et al. Contribution of antibody response to recombinant HIV-1 gene-encoded products nef, rev, tat, and protease in predicting development of AIDS in HIV-1-infected individuals. J Acquir Immune Defic Syndr 4 2 (1991) 165-172
45. Opi S., Peloponese Jr. J.M., Esquieu D., Campbell G., De Mareuil J., Walburger A., et al. Tat HIV-1 primary and tertiary structures critical to immune response against non-homologous variants. J Biol Chem 277 39 (2002) 35915-35919
46. Ruckwardt T.J., Tikhonov I., Berg S., Hatfield G.S., Chandra A., Chandra P., et al. Sequence variation within the dominant amino terminus epitope affects antibody binding and neutralization of human immunodeficiency virus type 1 Tat protein. J Virol 78 23 (2004) 13190-13196
47. McPhee D.A., Kemp B.E., Cumming S., Stapleton D., Gust I.D., and Doherty R.R. Recognition of envelope and tat protein synthetic peptide analogs by HIV positive sera or plasma. FEBS Lett 233 2 (1988) 393-396
48. Rodman T.C., To S.E., Hashish H., and Manchester K. Epitopes for natural antibodies of human immunodeficiency virus (HIV)-negative (normal) and HIV-positive sera are coincident with two key functional sequences of HIV Tat protein. Proc Natl Acad Sci USA 90 16 (1993) 7719-7723
49. Pilkington G.R., Duan L., Zhu M., Keil W., and Pomerantz R.J. Recombinant human Fab antibody fragments to HIV-1 Rev and Tat regulatory proteins: direct selection from a combinatorial phage display library. Mol Immunol 33 4-5 (1996) 439-450
50. Steinbrook R. One step forward, two steps back-will there ever be an AIDS vaccine?. N Engl J Med 357 26 (2007) 2653-2655